Drugs for rare diseases now account for 31% of R&D pipelines, up from 18% in 2010 and just 11% in 2005, according to a report from the Tufts Center for the Study of Drug Development. That's currently nearly 3,500 drugs in development, more than double the 1,530 in 2010.
In late May, Novartis AG's Avexis Inc. unit gained FDA approval for Zolgensma (onasemnogene neparvovec) to treat spinal muscular atrophy, and other companies are looking to follow suit developing drugs to treat a variety of diseases of the central nervous system (CNS).
In late May, Novartis AG's Avexis Inc. unit gained FDA approval for Zolgensma (onasemnogene neparvovec) to treat spinal muscular atrophy, and other companies are looking to follow suit developing drugs to treat a variety of diseases of the central nervous system (CNS).
Adding on to its $14 million series A round in April 2018, TFF Pharmaceuticals Inc. has secured another $8.17 million for the round to support development of its namesake thin film freezing (TFF) technology that was developed to increase the solubility of drugs.
Despite the strong growth in the number of drugs approved by the FDA over the last few years, clinical trial productivity fell 27% from 2013 to 2018, according to a report from the Iqvia Institute for Human Data Science.
Despite the strong growth in the number of drugs approved by the FDA over the last few years, clinical trial productivity fell 27% from 2013 to 2018, according to a report from the Iqvia Institute for Human Data Science.
Rather than develop vonoprazan in the U.S., Europe and Canada on its own, Takeda Pharmaceutical Co. Ltd. decided to spin the drug out into a new company, Phathom Pharmaceuticals Inc., with the help of venture capitalists at Frazier Healthcare Partners.
Looking to expand its glycogen synthase kinase-3 beta (GSK-3beta) inhibitor program, Northwestern University spinout Actuate Therapeutics Inc. has secured $21.7 million in a series B round led by Kairos Ventures. Defta Partners and Tech Coast Angels, with existing investor Bios Partners also participated in the round.
Rather than develop vonoprazan in the U.S., Europe and Canada on its own, Takeda Pharmaceutical Co. Ltd. decided to spin the drug out into a new company, Phathom Pharmaceuticals Inc., with the help of venture capitalists at Frazier Healthcare Partners.
